Hemp & Health as a Polish public company is traded on the Warsaw Stock Exchange (WSE:HMP).
The strategy of our Company presents merging activities in two complementary areas, namely:
1 / medical hemp/cannabis ("HEMP");
2 / products, services and unique medical technologies ("HEALTH").
HEMP
CBD and THC distribution
The Company intends to become the market leader in distribution of cannabis flowers, isolates and distillates containing high-percentage CBD, THC and other cannabinoids. We are creating our own suppliers and distribution network.
Private label
The Company sellCBD products in the formula of the "private label" service. This service consists of the development and production of products dedicated to a specific customer under his brand. These will be products based on hemp flowers, distillates and isolates with different concentrations of cannabinoids such as CBD or THC.
R&D
The company is currently working on an offer and documentation for the distribution in Poland of medical cannabis containing over 0.3% THC.
In cooperation with scientific research centres and companies operating in the field of pharmacy, the Company intends to buy or conduct research and development works in the field of medical use of cannabis. To this end, strategic partnerships will be established with international companies, in particular with companies from Canada and the USA.
HEALTH
Distribution
Ouroffer includes hemp and medical products, food packages, FMCG products and other products offered by partners. The full offer will be presented in the new online store launched by the Issuer.
We also specialize in the distribution of COVID-19 tests, both for professional and private use.
R&D
In cooperation with scientific research centers and companies from the USA and Canada, the Company intends to buy or conduct research and development works in the field of developing effective, unique and modern medical technologies. To this end, special purpose vehicles will be established, which will then obtain external financing for this type of activity. The technologies - after their development - will be reported to patent offices, and intellectual rights will indirectly, through special purpose vehicles, constitute the Company's assets.
Current situation
In connection with the outbreak of the war in Ukraine and the contacts with charity organizations and foundations supplying products to Ukraine, the Issuer's Management Board came to the conclusion that its activities should now focus on the distribution of products necessary for refugees from Ukraine and the military: both through a network of own contacts , as well as tenders to databases to which the Issuer has access.